Research & Publications †
( † Disclaimer: This search is powered by PubMed, a service of the U.S. National Library of Medicine. PubMed is a third-party website with no affiliation with Cleveland Clinic.)
Biographical Sketch
Richard A. Rudick, MD, is currently Professor of Medicine in the Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, the Hazel Prior Hostetler Chair of Neurology, Director of the Mellen Center for Multiple Sclerosis Treatment and Research, and Vice Chairman of Research and Development in the Neurological Institute at Cleveland Clinic.
Dr. Rudick graduated from Case Western Reserve University School of Medicine in 1975. Following internship and residency in medicine at the University of Connecticut, Dr. Rudick trained in neurology at the University of Rochester. During a postdoctoral research fellowship in the Center for Brain Research at the University of Rochester, studies focused on neurologic consequences of immune complex disease in animal systems and immunologic abnormalities in multiple sclerosis (MS) patients. Dr. Rudick’s subsequent studies on cerebrospinal fluid in MS were supported by an NIH clinical investigator career development award.
Dr. Rudick became Director of the Mellen Center in 1987. He has played key roles in several MS clinical trials, including pivotal registration trials of IFNß-1a (Avonex) and natalizumab (Tysabri) for relapsing-remitting MS. He continues studies on immunologic changes in MS patients, has led development of new clinical and imaging measures for MS trials and maintains a consultative clinical practice at the Mellen Center. Dr. Rudick has maintained continuous competitive grant funding from the NIH and the National Multiple Sclerosis Society for over 25 years.
Dr. Rudick established the Office of Clinical Research at Cleveland Clinic in 2001, and was the founding Chairman of the Division of Clinical Research in 2003. In that role, Dr. Rudick established a new General Clinical Research Center at Cleveland Clinic, secured a large Roadmap Clinical Research Training Program award from NIH (the Roadmap K12 Program), led a multidisciplinary effort to secure accreditation of the Cleveland Clinic Human Subjects Protection Program, and provided oversight for expansion of patient-based clinical and translational research. Dr. Rudick played a pivotal role in securing a Clinical and Translational Sciences Award from the NIH, serving as the CTSA Co-Principal Investigator. The CWRU/Cleveland Clinic CTSA created an academic home for clinical and translational research and city-wide infrastructure to support patient-based research.
Specialty Interests
Multiple Sclerosis, Neuroimmunology
Innovations & Patents
Dr. Rudick is a recognized pioneer in the treatment and research of multiple sclerosis (MS). As an internationally recognized thought leader in the MS field, he is invited to provide lectures and consultations regarding clinical research programs in MS worldwide.
Industry Relationships
Cleveland Clinic physicians and scientists may collaborate
with the pharmaceutical or medical device industries
to help develop medical breakthroughs or provide
medical education about recent trends. The
collaborations are reviewed as part of the Cleveland
Clinic’s procedures. The Cleveland Clinic publicly
discloses payments to its physicians and scientists
for speaking and consulting of
$5,000 or more per year, and any equity, royalties,
and fiduciary relationships in companies with which
they collaborate. In publicly disclosing this
information, the Cleveland Clinic tries to provide
information as accurately as possible about its
doctors’ connections with industry and those of their
immediate family members. As of 3/9/2010, Dr.
Rudick has reported the financial relationships
with the companies listed below. Patients should feel
free to contact their doctor about any of the
relationships and how the relationships are overseen
by the Cleveland Clinic. To learn more about the
Cleveland Clinic’s policies on collaborations with
industry and innovation management, go to
our Integrity in Innovation page.
Consulting. Dr. Rudick receives fees of $5,000 or more per year as a paid consultant or speaker for the following companies:
